Company profile
CELLECTIS S.A.
NASDAQ:CLLSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LASMECABTAGENE TIMGEDLEUCEL | phase1_2 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04150497 | phase1_2 | recruiting | 2019-10-14 | 2026-06-30 | Cellectis S.A. | Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) |
| NCT04106076 | phase1 | withdrawn | 2019-07-11 | 2019-12-05 | Cellectis S.A. | Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia |
| NCT04142619 | phase1 | terminated | 2019-11-21 | 2023-06-18 | Cellectis S.A. | Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) |
| NCT03190278 | phase1 | active_not_recruiting | 2017-06-19 | 2024-12-24 | Cellectis S.A. | Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
| NCT05607420 | phase1_2 | recruiting | 2022-11-01 | 2027-08-01 | Cellectis S.A. | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma |
FDA applications (0)
No records yet.